Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “AZD9291”

297 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 297 results

Early research (Phase 1)UnknownNCT04448379
What this trial is testing

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Shanghai JMT-Bio Inc. 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Testing effectiveness (Phase 2)Looking for participantsNCT07505173
What this trial is testing

Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer

Who this might be right for
Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases
Tianjin Medical University Cancer Institute and Hospital 74
Testing effectiveness (Phase 2)Active Not RecruitingNCT03778229
What this trial is testing

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

Who this might be right for
Carcinoma
AstraZeneca 367
Large-scale testing (Phase 3)Study completedNCT02959749
What this trial is testing

Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer

Who this might be right for
Progression Free Survival
Qingdao Central Hospital 147
Not applicableStudy completedNCT03918304
What this trial is testing

Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 923
Testing effectiveness (Phase 2)UnknownNCT05163249
What this trial is testing

Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Guangdong Association of Clinical Trials 44
Testing effectiveness (Phase 2)Active Not RecruitingNCT05526755
What this trial is testing

5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

Who this might be right for
Stage II-IIIB Non-small Cell Lung Carcinoma
AstraZeneca 188
Early research (Phase 1)UnknownNCT06362980
What this trial is testing

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations

Who this might be right for
NSCLC
National Cancer Center, China 20
Large-scale testing (Phase 3)Not Yet RecruitingNCT07376382
What this trial is testing

A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC

Who this might be right for
NSCLC
CSPC Megalith Biopharmaceutical Co.,Ltd. 680
Early research (Phase 1)Ended earlyNCT03418532
What this trial is testing

MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC

Who this might be right for
EGFR-mutated NSCLC (Disorder)
Molecular Partners AG 8
Not applicableUnknownNCT06174857
What this trial is testing

Efficacy of Osimertinib in Patients With Lung Cancer

Who this might be right for
Advanced Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital 100
Post-approval studies (Phase 4)Study completedNCT03853551
What this trial is testing

Osimertinib Study in Indian Patients

Who this might be right for
Non Small Cell Lung Cancer (NSCLC)
AstraZeneca 60
Large-scale testing (Phase 3)Looking for participantsNCT07738172
What this trial is testing

Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer

Who this might be right for
Lung Neoplasms, Non-Small Cell Lung Cancer
National Taiwan University Hospital 154
Early research (Phase 1)Study completedNCT02161770
What this trial is testing

Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

Who this might be right for
Solid Tumours
AstraZeneca 30
Early research (Phase 1)Active Not RecruitingNCT03567642
What this trial is testing

The Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers

Who this might be right for
Lung Cancer
Memorial Sloan Kettering Cancer Center 11
Not applicableLooking for participantsNCT06304441
What this trial is testing

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Who this might be right for
Leptomeningeal Metastasis
Guangzhou Medical University 100
Not applicableLooking for participantsNCT06726720
What this trial is testing

UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance

Who this might be right for
Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
AstraZeneca 300
Testing effectiveness (Phase 2)Active Not RecruitingNCT03381274
What this trial is testing

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

Who this might be right for
Carcinoma, Non-Small-Cell Lung
MedImmune LLC 43
Early research (Phase 1)Ended earlyNCT03891615
What this trial is testing

Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer

Who this might be right for
Lung Cancer
Massachusetts General Hospital 20
Next Page